EW News and Press, Edwards Lifesciences Corporation From 12/31/21

If you're weary of constantly hunting hot-story stocks and would rather just simplify your stock picking, you're in luck. You don't have to sacrifice performance by minimizing your trading activity, you only have to pick the right stocks to buy and hold for the long haul. Three familiar...

Wedgewood Partners’ 13F portfolio value increased ~3% from ~$690M to ~$709M this quarter. They added UnitedHealth and increased Taiwan Semi while reducing Starbucks, Keysight Technologies, and Alphabet. Their top five positions are at 37% of the overall portfolio. For...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

The ongoing resurgence of the pandemic could limit recovery in hospital procedure volumes and delay the rebound in MedTech procedures at least through early 2022, a team of analysts from Goldman Sachs argues. Issuing themes for portfolio set up in healthcare for 2022, the analysts led by Asad...

The global medical devices market is growing quickly, aided by substantial investment in technological advancement and the development of smart solutions. And the growing prevalence of chronic diseases and an aging population are driving market demand. Recently, medical devices stocks Edwards...

The FDA has approved the use of Edwards Lifesciences' (EW -3.0%)  SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for patients with severe pulmonary regurgitation. The use of Alterra makes up for variations in size and morphology of the right ventricular outflow trac...

EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR TRANSCATHETER PULMONIC VALVE REPLACEMENT PR Newswire IRVINE, Calif. , Dec. 20, 2021 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced it received approval from the U.S. Food and Dr...

Despite the ~31.1% YTD gain in its shares, JP Morgan has upgraded Edwards Lifesciences (EW +2.5%) to Overweight from Neutral, arguing that despite its recent outperformance, “there’s still more room to run.” The analysts led by Robbie Marcus think that company management ...

Ahead of its annual investor conference scheduled for today, Edwards Lifesciences (EW +1.7%) has reaffirmed its previously issued financial guidance for 2021. The health care equipment maker also announced its 2022 financial guidance indicating $5.5 - $6.0 billion in global sales for the year...

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference PR Newswire IRVINE, Calif. , Dec. 8, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's strategy for longer-term growth, provide an update on its ...